Boschetti M, Goglia U, Teti C, Esposito D, Giusti M, Minuto F, Ferone D
Department of Endocrinology and Medical Sciences, University of Genoa, Genoa, Italy.
J Endocrinol Invest. 2008 Sep;31(9 Suppl):85-90.
It is known that hypopituitarism reduces life expectancy and increases the risk of death for cardio- and cerebrovascular disease. Many studies report this phenomenon due to vascular diseases, and GH deficiency (GHD) seems to significantly contribute to the higher mortality. Aim of this article is to review the relationship between GH and cardiovascular risk factors to evaluate the beneficial effects of therapy in the adult GHD. GH replacement therapy (GHRT) improves insulin sensitivity, and reduces LDL cholesterol and triglyceride levels. Several studies also documented a decrease in the intima-media thickness at major arteries and improvement in microvascular and endothelial function. Other studies showed a decrease of inflammatory markers and the normalization of coagulation parameters. Finally, some authors have reported improvements in cardiac performance as well. These data evidence the positive effects of GHRT in the prevention of premature atherosclerosis in adults with GHD, and encourage the early administration of replacement therapy.
已知垂体功能减退会缩短预期寿命，并增加心血管和脑血管疾病的死亡风险。许多研究报道了这种由血管疾病导致的现象，而生长激素缺乏（GHD）似乎是导致较高死亡率的重要因素。本文的目的是综述生长激素与心血管危险因素之间的关系，以评估治疗对成年GHD患者的有益效果。生长激素替代疗法（GHRT）可改善胰岛素敏感性，降低低密度脂蛋白胆固醇和甘油三酯水平。多项研究还记录了主要动脉内膜中层厚度的减少以及微血管和内皮功能的改善。其他研究显示炎症标志物减少，凝血参数恢复正常。最后，一些作者也报道了心脏功能的改善。这些数据证明了GHRT对预防成年GHD患者过早发生动脉粥样硬化的积极作用，并鼓励早期给予替代治疗。
